Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away …
Post
-
-
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues …
-
Biogen proposes acquisition of partner Sage Therapeutics
Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following a year of significant challenges for the …
-
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small …
-
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its …
-
Small matter, big challenges: Nano milling in a sterilised environment
Nano milling involves transforming hydrophobic APIs into a water-soluble form and is achieved by reducing the API down in size …
-
Update: Johnson & Johnson acquires Intra-Cellular Therapies
Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company specialising in central nervous system disorder treatments. The …
-
JP Morgan 2025: GSK acquires IDRx in $1.15bn deal
GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for …
-
The promising future of regenerative medicine
Regenerative medicine aims to repair, augment, replace or regenerate damaged or diseased human cells, tissues, genes, organs or metabolic processes, …
-
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin G1(IgG1) antibody, …
-
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
CRISPR biotech Intellia Therapeutics has announced plans to reduce its workforce by 27% and halt early-stage R&D programmes as it …
-
FDA CDER director Patrizia Cavazzoni announces resignation
The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research …
-
Alzheimer’s total prevalent cases to reach 22.51 million in 8MM in 2033
Estimates by data analytics company GlobalData suggest that the total prevalent cases of Alzheimer’s disease (according to the DSM-IV criteria) …
-
Climb Bio enters licensing deal with Mabworks for CLYM116 development
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the anti-A proliferation-inducing ligand …
-
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
US-based biotech company A2 Biotherapeutics (A2 Bio) has secured $80m in funding to advance its pipeline of chimeric antigen receptor …
